Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Choudhury on the Use of Radiopharmaceuticals in Prostate Cancer

July 24th 2019

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses the use of radiopharmaceuticals in the treatment of patients with prostate cancer.

Dr. McGregor on the Goals of ADT in Prostate Cancer

July 23rd 2019

Pei-Chun McGregor, MD, cardio-oncologist and director of Ambulatory Cardiology at VA Boston Healthcare System, instructor in medicine, Brigham and Women’s Hospital, discusses the goals of androgen deprivation therapy (ADT) in the treatment of patients with prostate cancer.

Dr. Lee Highlights Key Takeaways From SPARTAN Trial in M0CRPC

July 20th 2019

Richard (Rick) JaeBong Lee, MD, PhD, medical oncologist at Massachusetts General Hospital, and assistant professor of medicine at Harvard Medical School, highlights key takeaways from the phase III SPARTAN trial in nonmetastatic castration-resistant prostate cancer.

Dr. Tagawa on Significance of BRCA2 With PSMA-Targeted Radionuclide Therapy in Prostate Cancer

July 17th 2019

Scott T. Tagawa, MD, discusses the impact of the BRCA2 mutation in patients with prostate cancer who are receiving prostate-specific membrane antigen–targeted radionuclide therapy.

Dr. Higano on the GETUG-AFU 16 Trial Results in Prostate Cancer

July 17th 2019

Celestia S. Higano, MD, discusses the outcomes of the GETUG-AFU 16 and its impact on current practices for prostate cancer.

Dr. Magi-Galluzzi on Preventing Overtreatment of Prostate Cancer

July 15th 2019

Cristina Magi-Galluzzi, MD, PhD, discusses the importance of properly diagnosing patients with prostate cancer to avoid overtreatment.

Enzalutamide Could Have Pivotal Role in Metastatic Hormone-Sensitive Prostate Cancer

July 12th 2019

Christopher Sweeney, MBBS, discusses the results of the ENZAMET trial and the next steps for researching the efficacy of enzalutamide in the treatment of patients with metastatic hormone-sensitive prostate cancer.

Dr. Yu on Rationale for the KEYNOTE-365 Study in mCRPC

July 9th 2019

Evan Y. Yu, MD, discusses the rationale behind the KEYNOTE-365 trial, looking at pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.

Lead Investigator Highlights Apalutamide Efficacy in Metastatic Castration-Sensitive Prostate Cancer

July 1st 2019

Kim Chi, MD, discusses how the next-generation androgen receptor inhibitor apalutamide in combination with androgen deprivation therapy could be a new standard of care for patients with metastatic castration-sensitive prostate cancer.

Dr. Choudhury on Targeted Therapy in Prostate Cancer

June 28th 2019

Dr. McGregor on the Goal of the PRONOUNCE Trial in Prostate Cancer

June 28th 2019

Pei-Chun McGregor, MD, cardio-oncologist and director of Ambulatory Cardiology at VA Boston Healthcare System, instructor in medicine, Brigham and Women’s Hospital, discusses the hope for the phase IIb PRONOUNCE trial in prostate cancer.

Update Shows Depth of Darolutamide Benefit in Nonmetastatic CRPC

June 27th 2019

Karim Fizazi, MD, PhD, discusses the impact of darolutamide on pain progression and quality of life in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Einstein on Treatment Approaches in Early Oligometastatic Prostate Cancer

June 26th 2019

David J. Einstein, MD, instructor of medicine, Harvard Medical School, attending physician, Beth Israel Deaconess Medical Center, discusses treatment approaches for patients with early evidence of oligometastatic prostate cancer.

Dr. Lee on the Role of Darolutamide in M0CRPC

June 25th 2019

Richard (Rick) JaeBong Lee, MD, PhD, medical oncologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses the role of darolutamide in nonmetastatic castration-resistant prostate cancer (M0CRPC).

Enzalutamide Improves rPFS Regardless of PSA Levels in Hormone-Sensitive Prostate Cancer

June 25th 2019

Enzalutamide in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer demonstrated significantly improved radiographic progression-free survival versus placebo plus ADT, regardless of baseline prostate-specific antigen levels, according to expanded findings from the ARCHES study.

Pembrolizumab Plus Olaparib Shows Potential in Heavily Pretreated mCRPC

June 24th 2019

Evan Y. Yu, MD, discusses updated data from cohort A of the KEYNOTE-365 trial in patients with metastatic castration-resistant prostate cancer.

Urologists Will Need Training in Immuno-Oncology Adverse Events

June 22nd 2019

As immunotherapy has become increasingly utilized, urologists are more frequently participating in the management of patients who are receiving immunotherapy.

Dr. Yu on Combining Pembrolizumab and Olaparib in mCRPC

June 21st 2019

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combining pembrolizumab and olaparib in metastatic castration-resistant prostate cancer.

Does Immuno-Oncology Therapy Have a Larger Role in the Urology Clinic?

June 21st 2019

The FDA approved indications in urologic cancers for 6 immune checkpoint inhibitors since 2015. That is unquestionably a good thing for patients, but the rise of these agents means that the role of the urologist in cancer care is changing, and some urologists are still on the fence about these agents.

Dr. Quinn on Novel Hormonal Therapies in Prostate Cancer

June 21st 2019

David I. Quinn, MD, MBBS, PhD, FRACP, FACP, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Department of Medicine, Keck School of Medicine, discusses the rise of novel hormonal therapies in prostate cancer.